Reinhard Dummer
Impact in
- Dermatology top 0.01%
- Cutaneous lymphoproliferative disorders research
- Oncology top 0.01%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
Papers in
- Oncology 438
- Cutaneous Melanoma Detection and Management 175
- CAR-T cell therapy research 164
- Cancer Immunotherapy and Biomarkers 132
-
- Melanoma and MAPK Pathways 253
- Co-authors
- Günter Burg (130 shared papers)Dirk Schadendorf (147 shared papers)Axel Hauschild (81 shared papers)Frank O. Nestlé (26 shared papers)Michel Gilliet (6 shared papers)Caroline Robert (106 shared papers)Mirjana Urosevic (36 shared papers)Paolo A. Ascierto (98 shared papers)
- Journals
- Journal of Clinical Oncology (131 papers)Annals of Oncology (68 papers)Dermatology (43 papers)European Journal of Cancer (41 papers)Melanoma Research (32 papers)
- Partner nations
- SwitzerlandGermanyUnited States
In The Last Decade
Reinhard Dummer
931 papers receiving 43.6k citations
Reinhard Dummer's Hit Papers
Peers
Comparison fields: 5 of 167
- Dermatology 7.7k
- Oncology 19.2k
- Immunology 12.8k
- Pathology and Forensic Medicine 4.7k
- Molecular Biology 16.9k
Countries citing papers authored by Reinhard Dummer
This map shows the geographic impact of Reinhard Dummer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reinhard Dummer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reinhard Dummer more than expected).
Fields of papers citing papers by Reinhard Dummer
This network shows the impact of papers produced by Reinhard Dummer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reinhard Dummer. The network helps show where Reinhard Dummer may publish in the future.
Co-authors
The 25 scholars most cited alongside Reinhard Dummer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 954 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells Hit paper breakdown → | 1998 | 2381 |
| 2 | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy Hit paper breakdown → | 2017 | 1165 |
| 3 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1071 |
| 4 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Hit paper breakdown → | 2018 | 1033 |
| 5 | Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Hit paper breakdown → | 2007 | 932 |
| 6 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Hit paper breakdown → | 2019 | 726 |
| 7 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2018 | 690 |
| 8 | The Genetic Evolution of Melanoma from Precursor Lesions Hit paper breakdown → | 2015 | 672 |
| 9 | Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2012 | 585 |
| 10 | Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Hit paper breakdown → | 2013 | 540 |
| 11 | In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States Hit paper breakdown → | 2008 | 532 |
| 12 | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Hit paper breakdown → | 2013 | 501 |
| 13 | 2009 | 484 | |
| 14 | 2008 | 418 | |
| 15 | Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2019 | 416 |
| 16 | 2006 | 411 | |
| 17 | Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2018 | 400 |
| 18 | 2013 | 340 | |
| 19 | 2004 | 324 | |
| 20 | 1999 | 318 |
About Reinhard Dummer
Reinhard Dummer is a scholar working on Oncology, Molecular Biology, Dermatology, Immunology and Pathology and Forensic Medicine, having authored 954 papers that have together received 44.4k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (253 papers), Cutaneous lymphoproliferative disorders research (191 papers), Cutaneous Melanoma Detection and Management (175 papers), CAR-T cell therapy research (164 papers), Cancer Immunotherapy and Biomarkers (132 papers), Immunotherapy and Immune Responses (122 papers), Lymphoma Diagnosis and Treatment (100 papers) and Nonmelanoma Skin Cancer Studies (57 papers). The work is most often cited by research in Dermatology (7.7k citations), Oncology (19.2k citations), Immunology (12.8k citations), Pathology and Forensic Medicine (4.7k citations) and Molecular Biology (16.9k citations). Reinhard Dummer has collaborated with scholars based in Switzerland, Germany and United States. Frequent co-authors include Günter Burg, Dirk Schadendorf, Axel Hauschild, Frank O. Nestlé, Michel Gilliet, Caroline Robert, Mirjana Urosevic, Paolo A. Ascierto, Selma Alijagic and Yuansheng Sun. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Dermatology, European Journal of Cancer and Melanoma Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.